MedTrace Logo

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

NCT05422183 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-06-16

No results posted yet for this study

Summary

This study is a single-arm, open-label, exploratory clinical study, the main purpose is to evaluate the combination of envafolimab, lenvatinib VP-16 in the treatment of platinum-resistant recurrent epithelial ovarian cancer，primary fallopian tube cancer and primary peritoneal carcinoma.

Conditions

  • Ovarian Cancer, Epithelial

Interventions

DRUG

Envafolimab

400mg，sc，d1，Q3W

DRUG

Lenvatinib

8 mg(BW\<60 kg) OR 12 mg(BW≥60 kg)，po，qd，d1-21，Q3W

DRUG

VP-16

50 mg/d, po,d1-14，Q3W

Sponsors & Collaborators

  • Zhongda Hospital

    lead OTHER

Principal Investigators

  • Yang Shen, MD · Zhongda Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-30
Primary Completion
2022-12-30
Completion
2023-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05422183 on ClinicalTrials.gov